Hantavirus global briefing — August 31, 2026: ECDC week 35 adds no new signal as a broad assay enters the watchlist

Executive read

The latest official European bulletin adds a date, not a new hantavirus event. ECDC's week-35 Communicable Disease Threats Report, published on 28 August and covering 22–28 August, lists several active threats but contains no hantavirus or Andes-virus item. 1

Germany's latest RKI bulletin remains the newest country-level European denominator available here: 10 notifications in reporting week 34, 188 in weeks 1–34 of 2026, compared with 201 in the same period of 2025. 2

France's National Reference Centre recorded 19 confirmed infections from January through March 2026. The ANRS page updated on 24 August says that count is in line with the French monthly average. 3

The new research signal is diagnostic. Hepp and colleagues describe HantAmeriQ, a broadly reactive real-time PCR assay that detected all New World orthohantaviruses known to cause human disease in synthetic-RNA testing. Its limit of detection ranged from 25 to 28,000 copies per reaction, depending on the virus. The assay performed as well as or better than a commercial assay for North American viruses, while South American performance was weaker. 4

The current reading is therefore restrained: the latest European threat bulletin does not add a new hantavirus signal, Germany's notification stream remains below its 2025 comparison through week 34, and the main incremental value today is a surveillance-capacity advance rather than a newly documented global outbreak.

Human surveillance

Europe

The RKI table in Epidemiologisches Bulletin 35/2026 was published on 27 August. Its hantavirus row reports the following comparable figures:

Jurisdiction and period	Notifications	Comparison	What the number describes
Germany, reporting week 34 of 2026	10	Weekly count	Notifications received by local health offices in the stated week. 2
Germany, weeks 1–34 of 2026	188	—	Year-to-date notifications through the bulletin's reporting cut-off. 2
Germany, weeks 1–34 of 2025	201	13 more than 2026	RKI's same-window comparator. 2

The week-34 count is higher than the five notifications recorded for week 33 in the preceding bulletin, while the year-to-date total remains lower than the 2025 comparator. Germany's figures describe a national notification stream; they do not establish a Europe-wide trend.

The ANRS page provides France's latest accessible national reference-centre signal. The CNR for Hantaviruses at the Institut Pasteur recorded 19 recent infections between January and March 2026, a count described as consistent with the French monthly average. The page gives no strain-by-strain breakdown, exposure table or later national total. 3

ECDC separately published an epidemiological update on 20 August after French authorities reported an imported Andes-hantavirus infection on 6 August. The traveller had stayed in France from 19 July to 2 August, developed mild symptoms, received medical care without hospitalisation, and had been symptom-free since 28 July. Spain received the notification after the traveller left France, and authorities began contact follow-up in France and Spain. 5

ECDC assessed the risk to the general EU/EEA population as very low. The assessment rests on the likely acquisition of infection in Argentina, the absence of the Andes-virus rodent reservoir in Europe, and the public-health measures under way. 5

Americas, Asia-Pacific and the daily window

The 29–31 August scan produced no additional authoritative national human denominator from the Americas, Asia-Pacific or another region that can be added without mixing reporting periods or relying on a secondary claim. The available France and Germany figures above therefore remain separate surveillance anchors rather than components of a global total.

Chile's latest quantified balance remains the 49 confirmed infections and 19 deaths attributed to the Ministry of Health's epidemiological bulletin in reporting published before this issue. That balance belongs to the previous issue's evidence window and is carried here only as context; this edition adds no new Chilean count. The Pine Ridge alert likewise has no newly disclosed case count, strain or fatality figure in the accessible material.

Official posture

ECDC's week-35 report is the main late-August international status change. The report covers 22–28 August and names diphtheria, Ebola, swine influenza A(H1N2), respiratory-virus epidemiology, Crimean-Congo haemorrhagic fever, dengue, chikungunya, Vibrio growth, West Nile virus, cholera, poliovirus and expert deployments. Hantavirus and Andes virus do not appear in the report's topic list or PDF text. 1

That result is a bounded surveillance finding: the ECDC report adds no hantavirus item for its covered week. It leaves national surveillance channels, including the RKI bulletin, as the relevant source for country-level incidence.

The latest accessible CDC situation page is an archive page dated 7 July 2026. The current readable CDC hantavirus health update is HAN-00529, published 18 May. CDC describes that document as a Health Update rather than a new Health Alert or Health Advisory. The guidance asks clinicians to consider Andes virus after exposure to the M/V Hondius outbreak and to test other hantaviruses when compatible illness follows rodent exposure. 6 7

WHO's current closure boundary remains the 2 July statement that the M/V Hondius outbreak was over at 13 cases and three deaths, after more than 650 contacts had been followed in 33 countries and territories. That event remains separate from the routine rodent-linked surveillance figures in Germany, France and Chile. 8

Reservoir and exposure context

The ANRS describes the usual transmission route as inhalation of aerosols contaminated by urine or faeces from infected rodents. The page identifies wild rodents as the main reservoirs and places most human exposure in rural settings such as forests, fields and farms. 3

The page also separates the major clinical patterns. European and Asian hantaviruses more often produce haemorrhagic fever with renal syndrome, while American hantaviruses more often produce pulmonary disease. The ANRS gives approximate fatality ranges of 0.4–10% for the renal syndrome and 30–60% for severe cardiopulmonary disease. 3

No new dated rodent-abundance survey, reservoir-infection prevalence estimate or environmental-sampling result was verified for 29–31 August. The biological pathway above explains why field exposure remains relevant; it is not a real-time estimate of rodent activity in any particular region.

Research watch

HantAmeriQ: a broad New World assay

Authors and venue: Susan E. Hepp, Mojgan Deldari, Jeffery Arcilla and colleagues; Journal of Clinical Virology, online 6 August 2026, volume 186, article 105989. DOI: 10.1016/j.jcv.2026.105989. 4
Design: The authors adapted an existing Sin Nombre virus rRT-PCR primer-probe set into HantAmeriQ, a pan-American assay intended for human diagnosis and rodent surveillance. 4
Materials: Synthetic RNA established the detection limit. Rodent and human specimens from the United States, Central America and South America tested the assay across genetically diverse viruses. 4
Quantitative result: The assay detected all New World orthohantaviruses known to cause human disease in the synthetic-RNA panel. Detection limits ranged from 25 copies per reaction for Blue River virus to 28,000 copies per reaction for Bayou virus. 4
Practical relevance: A single broad assay could support early screening across a diverse New World virus panel and could be used in rodent-centred field surveillance, subject to local validation and laboratory capacity. This is a potential use described by the study's design, not evidence that the assay has been adopted by national programmes.
Limitation: The assay performed as well as or better than a commercial assay for North American hantaviruses, while it performed less well for South American hantaviruses. The abstract does not provide a single sensitivity or specificity estimate across all clinical settings. 4

A second August review places the diagnostic problem inside mass-gathering preparedness. Asokan, Pandey and colleagues review cruise tourism, religious events, refugee settlements, sports events and temporary accommodation, and identify delayed diagnosis, underreporting, limited environmental surveillance and missing event-specific preparedness frameworks as persistent problems. The review is qualitative and reports no new case denominator or effect estimate, so it is a background reference rather than a new surveillance result. 9

The two research items address different bottlenecks. HantAmeriQ targets breadth and turnaround in laboratory detection, while the mass-gathering review targets the operational conditions in which delayed recognition and passenger dispersal complicate response. Neither item changes the current case counts.

What would change the assessment

A later RKI bulletin with a material rise in weekly notifications or a new national European report would change the European comparison.
A new Chilean, Argentine, US or Asia-Pacific health-authority table with a defined reporting cut-off would add a current regional denominator.
A Pine Ridge update naming human cases, virus type, exposure setting or fatalities would convert the alert into a case-level event.
A dated rodent-abundance, reservoir-infection or environmental-sampling result would add a quantitative ecological signal.
Clinical validation of HantAmeriQ in larger, geographically diverse specimen panels would clarify whether its broad laboratory coverage translates into routine surveillance performance.

For 31 August, the evidence supports a narrow conclusion: ECDC's newest weekly threat report contains no hantavirus item; Germany reports 188 notifications through week 34, below its 2025 comparator; France's reference centre reports 19 cases for January–March; and the most useful new research signal is a broad New World assay whose detection limits vary sharply by virus and whose South American performance still needs validation.